

Invitation to the presentation of SenzaGen's Q3 2025 interim report

Lund, October 29, 2025

SenzaGen's 2025 Q3 report will be published on Nov 5, 2025, at 07:30 AM, followed by a live webcast presentation at 10:00 on the same day. The presentation will be given by SenzaGen's President and CEO, Peter Nählstedt, with a subsequent Q&A session moderated by Rodney Alfvén, partner at Hallvarsson & Halvarsson.

The presentation will be held in Swedish.

Time: Wednesday, Nov 5, 10:00

Webcast

If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions:

<https://senzagen.events.inderes.com/q3-report-2025>

Teleconference

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference:

<https://events.inderes.com/senzagen/q3-report-2025/dial-in>

The presentation can also be viewed later on SenzaGen's website: <https://senzagen.com/investors/presentations/>

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB

Email: peter.nahlstedt@senzagen.com | Tel: +46 46-275 62 00

Tina Dackemark Lawesson, VP Marketing & Communications

Email: tina.lawesson@senzagen.com | Tel: +46 46-275 62 00



About us

SenzaGen is a corporate group on its way to becoming a leading player in non-animal testing, driving the shift from animal experiments to methods that more accurately reflect human biology. Leveraging cutting-edge technology, the company offers high-performance non-animal test methods and expert advisory services. These methods are more effective, precise, and cost-efficient than traditional animal-based approaches and contribute to a substantial reduction in the number of laboratory animals used worldwide. SenzaGen's growth strategy focuses on strengthening its position in both established and new markets through direct sales, complementary partnerships, an expanded test portfolio, and recognized thought leadership. The company also maintains a long-term acquisition agenda to accelerate commercial potential. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden, along with subsidiaries in Italy and the USA. For more information, visit www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company's Certified Adviser.

Attachments

[Invitation to the presentation of SenzaGen's Q3 2025 interim report](#)